277 related articles for article (PubMed ID: 27286723)
1. A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration.
Kumar P; Thudium E; Laliberte K; Zaccardelli D; Nelsen A
Clin Pharmacokinet; 2016 Dec; 55(12):1495-1505. PubMed ID: 27286723
[TBL] [Abstract][Full Text] [Related]
2. Oral treprostinil for the treatment of pulmonary arterial hypertension.
de Lartigue J
Drugs Today (Barc); 2014 Aug; 50(8):557-65. PubMed ID: 25187906
[TBL] [Abstract][Full Text] [Related]
3. Treprostinil for the treatment of pulmonary arterial hypertension.
Torres F; Rubin LJ
Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension.
White RJ; Torres F; Allen R; Jerjes C; Pulido T; Yehle D; Howell M; Laliberte K; Marier JF; Tapson VF
J Cardiovasc Pharmacol; 2013 Jun; 61(6):474-81. PubMed ID: 23328389
[TBL] [Abstract][Full Text] [Related]
5. Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience.
Coons JC; Miller T
Ther Adv Respir Dis; 2018; 12():1753466618766490. PubMed ID: 29609511
[TBL] [Abstract][Full Text] [Related]
6. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
LeVarge BL; Channick RN
Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
[TBL] [Abstract][Full Text] [Related]
7. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.
Voswinckel R; Reichenberger F; Enke B; Kreckel A; Krick S; Gall H; Schermuly RT; Grimminger F; Rubin LJ; Olschewski H; Seeger W; Ghofrani HA
Pulm Pharmacol Ther; 2008 Oct; 21(5):824-32. PubMed ID: 18657627
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
[TBL] [Abstract][Full Text] [Related]
9. Comparative bioavailability of inhaled treprostinil administered as LIQ861 and Tyvaso® in healthy subjects.
Roscigno RF; Vaughn T; Parsley E; Hunt T; Eldon MA; Rubin LJ
Vascul Pharmacol; 2021 Jun; 138():106840. PubMed ID: 33545364
[TBL] [Abstract][Full Text] [Related]
10. Transitioning Parenteral or Inhaled Treprostinil to Oral Treprostinil Diolamine: Case Series and Review of the Literature.
Smith ZR; Kelly B; Awdish RL; Hegab S
J Pharm Pract; 2019 Oct; 32(5):599-604. PubMed ID: 29558853
[TBL] [Abstract][Full Text] [Related]
11. The role of treprostinil in the management of pulmonary hypertension.
Skoro-Sajer N; Lang I
Am J Cardiovasc Drugs; 2008; 8(4):213-7. PubMed ID: 18690755
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic evaluation of treprostinil (oral) for the treatment of pulmonary arterial hypertension.
Hellawell JL; Bhattacharya S; Farber HW
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1445-53. PubMed ID: 25204984
[TBL] [Abstract][Full Text] [Related]
13. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.
McLaughlin VV; Palevsky HI
Clin Chest Med; 2013 Dec; 34(4):825-40. PubMed ID: 24267307
[TBL] [Abstract][Full Text] [Related]
14. Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series.
Ackerbauer KA; Tandon R
J Pharm Pract; 2018 Apr; 31(2):163-166. PubMed ID: 28464760
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment.
Peterson L; Marbury T; Marier J; Laliberte K
J Clin Pharm Ther; 2013 Dec; 38(6):518-23. PubMed ID: 24033615
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations.
Mathier MA; McDevitt S; Saggar R
J Heart Lung Transplant; 2010 Nov; 29(11):1210-7. PubMed ID: 20855220
[TBL] [Abstract][Full Text] [Related]
17. Inhaled treprostinil: a therapeutic review.
Channick RN; Voswinckel R; Rubin LJ
Drug Des Devel Ther; 2012; 6():19-28. PubMed ID: 22291467
[TBL] [Abstract][Full Text] [Related]
18. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
Gessler T; Seeger W; Schmehl T
Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
[TBL] [Abstract][Full Text] [Related]
20. Treprostinil for the treatment of pulmonary arterial hypertension in patients with New York Heart Association class II-IV symptoms.
Herald N; Laliberte K
Pharmacotherapy; 2006 Aug; 26(8):1203; discussion 1203-4. PubMed ID: 16863500
[No Abstract] [Full Text] [Related]
[Next] [New Search]
